Abstract
Intravitreal injection of bevacizumab has been shown to satisfactorily treat retinopathy of prematurity; nevertheless, the safety of antivascular endothelial growth factor therapy in children remains uncertain. We report a patient with bilateral, zone 1, stage 3 plus retinopathy of prematurity who was treated with combined laser photocoagulation and intravitreal ranibizumab injection and demonstrated full regression at 3 months after injection but then developed bilateral retinal detachments 1 month later.
Copyright © 2010. Published by Mosby, Inc.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Humans
-
Infant, Newborn
-
Infant, Premature
-
Intravitreal Injections
-
Male
-
Ranibizumab
-
Retinal Detachment / diagnostic imaging
-
Retinal Detachment / etiology*
-
Retinal Detachment / pathology
-
Retinopathy of Prematurity / drug therapy*
-
Time Factors
-
Ultrasonography
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Ranibizumab